Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
暂无分享,去创建一个
D Tripathy | B. Weber | J. Baselga | D. Tripathy | D. Hayes | D. Slamon | M. Pegram | J. Glaspy | D. Slamon | A. Lipton | D F Hayes | J A Glaspy | S. Baughman | T. Twaddell | A Lipton | D J Slamon | B L Weber | M D Pegram | T Twaddell | J M Baselga | D Baly | S A Baughman | D. Baly | Debbie Baly
[1] Takuma Sasaki,et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.
[2] A. Eastman,et al. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. , 1992, The Journal of clinical investigation.
[3] N. Bachur,et al. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. , 1980, Cancer clinical trials.
[4] E. Felip,et al. Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy , 1995, Cancer.
[5] M. Pike,et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. , 1994, Cancer research.
[6] A. Gazdar,et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.
[7] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[8] B. Groner,et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.
[9] C. Macleod,et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. , 1990, The Journal of clinical investigation.
[10] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[11] R. Finn,et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.
[12] D. Slamon,et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.
[13] S. Lippard,et al. Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.
[14] L. Presta,et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Sela,et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.
[16] A. Ullrich,et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.
[17] A. Muscella,et al. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. , 1993, Cancer letters.
[18] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[19] S. Wingren,et al. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. , 1994, Cytometry.
[20] P. Toy,et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. , 1991, Cancer research.
[21] D. Slamon,et al. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.
[22] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[23] R. Bast,et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .
[24] D. Crothers,et al. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[25] C. Arteaga,et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.
[26] N. Ibrahim,et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.
[27] J. Roberts,et al. Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds , 1972, Nature.
[28] B. Rosenberg. Possible mechanisms for the antitumor activity of platinum coordination complexes. , 1975, Cancer chemotherapy reports.
[29] R. Gelman,et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Lippard,et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.
[32] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Marshall,et al. Preclinical and clinical experience with cisplatin resistance. , 1995, Hematology/oncology clinics of North America.
[34] J. Izbicki,et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.
[35] M. Fernö,et al. ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.
[36] G. Hortobagyi,et al. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. , 1978, Cancer treatment reports.
[37] C. Kotts,et al. ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. , 1990, Journal of immunological methods.
[38] R. Wittes,et al. Cisplatin in the treatment of metastatic breast carcinoma A prospective randomized trial of two dosage schedules , 1982, American journal of clinical oncology.
[39] V. Chinchilli,et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] T. Visakorpi,et al. Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.
[41] L. Demers,et al. Serial serum c‐erbB‐2 levels in patients with breast carcinoma , 1996, Cancer.